| Simulation of activator–inhibitor dynamics based on cross-diffusion Brusselator reaction–diffusion system via a differential quadrature-radial point interpolation method (DQ … M Abassazadeh, M Golmohamammadi, M Dehghan The European Physical Journal Plus 136, 2021 | 5 | 2021 |
| A novel risk assessment metric for antimyeloma therapies and drug interactions. X Xu, M Jaberi-Douraki, F Anwer, B Faiman, L Williams, SA Mazzoni, ... Journal of Clinical Oncology 41 (16_suppl), e24082-e24082, 2023 | 1 | 2023 |
| Disparities in multiple myeloma: A global perspective on drug toxicity trends. M Jaberi-Douraki, X Xu, B Faiman, G Wyckoff, J Riviere, J Khouri, ... Journal of Clinical Oncology 41 (16_suppl), 8015-8015, 2023 | 1 | 2023 |
| Identification of genes encoding targets associated with adverse events in multiple myeloma. X Xu, S Raza, NM Gadara, RA Ramachandran, J Riviere, ... Journal of Clinical Oncology 41 (16_suppl), 1556-1556, 2023 | 1 | 2023 |
| Pooled Analysis on Bispecific Antibody-Related Toxicities in Multiple Myeloma M Golmohammadi, D Dima, M Albayyadhi, A Moradi, S Raza, ... Blood 142, 1953, 2023 | | 2023 |
| P-465 Global disparities in multiple myeloma: examining adverse events and drug toxicity trends M Jaberi-Douraki, X Xu, RA Ramachandran, B Faiman, F Anwer, ... Clinical Lymphoma Myeloma and Leukemia 23, S295-S296, 2023 | | 2023 |
| P-375 Unraveling signaling pathways in multiple myeloma cardiovascular toxicities from pharmacovigilance and pharmacogenomics data mining X Xu, S Raza, J Zhang, RA Ramachandran, B Faiman, F Anwer, ... Clinical Lymphoma Myeloma and Leukemia 23, S246-S247, 2023 | | 2023 |
| P-366 Signaling pathway data analytics of nephropathy and neuropathy from drug toxicities in multiple myeloma S Raza, X Xu, J Zhang, RA Ramachandran, B Faiman, F Anwer, ... Clinical Lymphoma Myeloma and Leukemia 23, S241, 2023 | | 2023 |
Majid Jaberi-DourakiKansas State UniversityVerified email at k-state.edu
